|
1
|
Ando K, Heymann MF, Stresing V, Mori K,
Rédini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014.PubMed/NCBI
|
|
3
|
Sun L, Li Y, Zhang J, Li H, Li B and Ye Z:
Prognostic value of pathologic fracture in patients with high grade
localized osteosarcoma: A systemic review and meta-analysis of
cohort studies. J Orthop Res. 33:131–139. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Broadhead ML, Clark JC, Myers DE, Dass CR
and Choong PF: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Poletajew S, Fus L and Wasiutynski A:
Current concepts on pathogenesis and biology of metastatic
osteosarcoma tumors. Ortop Traumatol Rehabil. 13:537–545. 2011.(In
English, Polish). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:336–338.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu J: Control of protein synthesis and
mRNA degradation by microRNAs. Curr Opin Cell Biol. 20:214–221.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nouraee N and Mowla SJ: miRNA therapeutics
in cardiovascular diseases: Promises and problems. Front Genet.
6:2322015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aigner A: MicroRNAs (miRNAs) in cancer
invasion and metastasis: Therapeutic approaches based on
metastasis-related miRNAs. J Mol Med (Berl). 89:445–457. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rottiers V and Näär AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho WC: MicroRNAs: Potential biomarkers
for cancer diagnosis, prognosis and targets for therapy. Int J
Biochem Cell Biol. 42:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: A microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chistiakov DA and Chekhonin VP:
Contribution of microRNAs to radio- and chemoresistance of brain
tumors and their therapeutic potential. Eur J Pharmacol. 684:8–18.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fan W, Huang J, Xiao H and Liang Z:
MicroRNA-22 is downregulated in clear cell renal cell carcinoma,
and inhibits cell growth, migration and invasion by targeting PTEN.
Mol Med Rep. 13:4800–4806. 2016.PubMed/NCBI
|
|
17
|
Wei ZJ, Tao ML, Zhang W, Han GD, Zhu ZC,
Miao ZG, Li JY and Qiao ZB: Up-regulation of microRNA-302a
inhibited the proliferation and invasion of colorectal cancer cells
by regulation of the MAPK and PI3K/Akt signaling pathways. Int J
Clin Exp Pathol. 8:4481–4491. 2015.PubMed/NCBI
|
|
18
|
Zhang GM, Bao CY, Wan FN, Cao DL, Qin XJ,
Zhang HL, Zhu Y, Dai B, Shi GH and Ye DW: MicroRNA-302a suppresses
tumor cell proliferation by inhibiting AKT in prostate cancer. PLoS
One. 10:e01244102015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang Z, Bian X and Shim H: Inhibition of
breast cancer metastasis with microRNA-302a by downregulation of
CXCR4 expression. Breast Cancer Res Treat. 146:535–542. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang Z, Ahn J, Guo D, Votaw JR and Shim
H: MicroRNA-302 replacement therapy sensitizes breast cancer cells
to ionizing radiation. Pharm Res. 30:1008–1016. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo T, Yu W, Lv S, Zhang C and Tian Y:
MiR-302a inhibits the tumorigenicity of ovarian cancer cells by
suppression of SDC1. Int J Clin Exp Pathol. 8:4869–4880.
2015.PubMed/NCBI
|
|
22
|
Wang Y, Zhao L, Xiao Q, Jiang L, He M, Bai
X, Ma M, Jiao X and Wei M: miR-302a/b/c/d cooperatively inhibit
BCRP expression to increase drug sensitivity in breast cancer
cells. Gynecol Oncol. 141:592–601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao L, Wang Y, Jiang L, He M, Bai X, Yu L
and Wei M: MiR-302a/b/c/d cooperatively sensitizes breast cancer
cells to adriamycin via suppressing P-glycoprotein (P-gp) by
targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res.
35:252016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blobel CP: ADAMs: Key components in EGFR
signalling and development. Nat Rev Mol Cell Biol. 6:32–43. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J, Qi J, Chen N, Fu W, Zhou B and He
A: High expression of a disintegrin and metalloproteinase-9
predicts a shortened survival time in completely resected stage I
non-small cell lung cancer. Oncol Lett. 5:1461–1466.
2013.PubMed/NCBI
|
|
27
|
Li J, Ji Z, Qiao C, Qi Y and Shi W:
Overexpression of ADAM9 promotes colon cancer cells invasion. J
Invest Surg. 26:127–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS,
Shin YK, Zhang X, Park KH, Park SW, Chung HC and Powis G: The
effect of disintegrin-metalloproteinase ADAM9 in gastric cancer
progression. Mol Cancer Ther. 13:3074–3085. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sung SY, Kubo H, Shigemura K, Arnold RS,
Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, et al:
Oxidative stress induces ADAM9 protein expression in human prostate
cancer cells. Cancer Res. 66:9519–9526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang L, Gong F and Cui Y: RNAi-mediated A
disintegrin and metalloproteinase 9 gene silencing inhibits the
tumor growth of non-small lung cancer in vitro and in vivo. Mol Med
Rep. 12:1197–1204. 2015.PubMed/NCBI
|
|
31
|
Martin AC, Cardoso AC, Selistre-de-Araujo
HS and Cominetti MR: Recombinant disintegrin domain of human ADAM9
inhibits migration and invasion of DU145 prostate tumor cells. Cell
Adh Migr. 9:293–299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen CM, Hsieh YH, Hwang JM, Jan HJ, Hsieh
SC, Lin SH and Lai CY: Fisetin suppresses ADAM9 expression and
inhibits invasion of glioma cancer cells through increased
phosphorylation of ERK1/2. Tumour Biol. 36:3407–3415. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang L, He A, Zhang Q and Tao C: miR-126
inhibits cell growth, invasion, and migration of osteosarcoma cells
by downregulating ADAM-9. Tumour Biol. 35:12645–12654. 2014.
View Article : Google Scholar : PubMed/NCBI
|
